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ABSTRACT 
Objective.  To identify accurate predictors for the risk of sudden death in patients with 
familial dysautonomia (FD). 
Methods. Ten-minute resting high-fidelity 12-lead ECGs were obtained from 14 FD 
patients and 14 age/gender-matched healthy subjects. Multiple conventional and 
advanced ECG parameters were studied for their ability to predict sudden death in FD 
over a subsequent 4.5-year period, including multiple indices of linear and non-linear 
heart rate variability (HRV); QT variability; waveform complexity; high frequency QRS; 
and derived Frank-lead parameters.   
Results. Four of the 14 FD patients died suddenly during the follow-up period, usually 
with concomitant pulmonary disorder. The presence of low vagally-mediated HRV was 
the ECG finding most predictive of sudden death.  Concomitant left ventricular 
hypertrophy and other ECG abnormalities such as increased QTc and JTc intervals, 
spatial QRS-T angles, T-wave complexity, and QT variability were also present in FD 
patients, suggesting that structural heart disease is fairly common in FD. 
Conclusion. Although excessive or unopposed cardiac vagal (relative to sympathetic) 
activity has been postulated as a contributor to sudden death in FD, the presence of low 
vagally-mediated HRV was “paradoxically” the best predictor of sudden death. However, 
we suggest that low vagally-mediated HRV be construed not as a direct cause of sudden 
death in FD, but rather as an effect of concurrent pathological processes, especially 
hypoxia due to pulmonary disorders and sleep apnea, that themselves increase the risk of 
sudden death in FD and simultaneously diminish HRV. We speculate that adenosine may 
play a role in sudden death in FD, possibly independently of vagal activity, and that 
adenosine inhibitors such as theophylline might therefore be useful as prophylaxis in this 
disorder. 
  
Keywords: heart rate variability, bradycardia, signal averaged ECG, QT interval, QRS-T 
angle, T-wave morphology, hypoxia, adenosine, methylxanthines, theophylline, left 
ventricular hypertrophy. 
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INTRODUCTION 
 
Familial dysautonomia (FD), or hereditary sensory and autonomic neuropathy  
type III, is a rare autosomal recessive disorder with extensive central and  
peripheral autonomic perturbations as well as small-fiber sensory dysfunction1. Most FD 
patients still die before the age of 50 and have cardiac autonomic dysfunction and an 
increased risk of sudden death believed to be mediated especially through respiratory 
failure and fatal bradyarrhyhmias2-5.  Presently however, there are no sensitive and 
specific predictors to identify which patients with FD are at risk of sudden death.  
Although prolonged corrected QT (QTc) and JTc intervals can be life-threatening and 
have been described in 20-33% FD patients6, ventricular arrhythmias (including torsades 
de pointes) have not been previously described in FD5. On the other hand, diminished 
cardiac sympathetic activity with relatively preserved or unopposed cardiac vagal activity 
has been hypothesized to be an important mediator of sudden death in FD1,6,7. Although 
low heart rate variability (HRV) is recognized for its ability to predict mortality or sudden 
death in other clinical conditions8, low HRV might be expected to be a rather poor 
predictor for sudden death in FD if indeed vagally-mediated fluctuations (the major 
contributor to HRV9) are relatively preserved compared to sympathetically-mediated 
fluctuations in FD.  In this study, we investigated the ability of several advanced ECG 
parameters, including advanced HRV, to predict sudden death in a small group of FD 
patients.  Secondarily, we also investigated differences in these same parameters between 
FD patients and a group of age- and gender matched healthy control subjects. Although 
myocardial infarction and structural cardiac disease have occasionally been noted FD3,10, 
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such conditions have not been electrocardiographically well-characterized in groups of 
FD patients. Our principal hypotheses were that one or more advanced ECG parameters 
would be accurate in predicting the occurrence of sudden death in FD patients over a 4.5-
year follow up period, and that electrocardiographic evidence of structural heart disease 
would also be found in at least some FD patients.  
 
METHODS  
 
Patients.  Ten-minute resting high-fidelity 12-lead ECGs were recorded in 14 FD 
patients (age range; 13-51 years; mean 25.3 ± 12.7 years) and in 14 age/gender-matched 
healthy subjects (age range; 14-42 years; mean 24.6 ± 8.0 years). Both groups consisted 
of six females and eight males. All FD patients were homozygous recessive for the 
common FD (IKBKAP) intron gene mutation and met clinical diagnostic criteria as they 
were of Ashkenazi Jewish extraction, lacked lingual fungiform papillae, did not have an 
axon flare after intradermal histamine, had decreased or absent deep tendon reflexes, and 
lacked overflow tears11. All control subjects were asymptomatic and had normal 12-lead 
electrocardiograms. Informed consent was obtained from all subjects prior to study. For 
subjects less than 21 years of age, signatures were obtained from both the participant and 
a parent.  
Data collection.  Data collection was approved by the Institutional Review Boards 
of the New York University Medical Center (New York, NY) and NASA’s Johnson 
Space Center (Houston, TX).  A PC-based ECG system with a frequency response to 300 
Hz and a sampling rate of 1000 samples/s (CardioSoft Enhanced Cardiology, Houston, 
TX, or Cardiax, IMED Co Ltd, Budapest, Hungary) was used to simultaneously acquire 
the 12-lead conventional and advanced ECG data. Data collection for all FD patients took 
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place during a 1-week period in the spring of 2003. ECG data were collected until at least 
256 beats were accepted for signal averaging and for variability analyses, as outlined 
below. Eleven of the FD patients also had echocardiographic results available based on 
incidental studies that had been (or were later) conducted for clinical purposes.  
Analysis of ECG signals.   
A. Conventional ECG parameters.  Signals from the conventional ECG were 
analyzed automatically in software with respect to the heart rate, the PR, QRS, QT/QTc 
and JT/JTc intervals (Bazett-corrected), the frontal plane QRS and T-wave axes, and the 
presence of left ventricular hypertrophy by either the Cornell or Sokolow-Lyon criteria12.  
In addition, Anderson et al’s subset of Sylvester’s criteria13 was applied to determine, in 
an objective fashion, the presence on the conventional ECG of a prior myocardial 
infarction.  
B. Advanced ECG parameters derived from signal averaging.  Signal averaging 
was performed using software developed by the authors at NASA’s Johnson Space 
Center14,15 in order to generate results for all of the following advanced ECG techniques: 
1) 12-lead High Frequency (HF) QRS ECG14; 2) Frank-lead ECG parameters (derived 
from the 12-lead ECG using the reconstruction technique of Kors et al16), including late 
potentials-related parameters17 and several other parameters related to the “spatial” (“3-
dimensional”) ECG (see below); and 3) several parameters of waveform complexity (P, 
QRS and T) derived from singular value decomposition (SVD)18 plus signal averaging15. 
In brief, the software automatically aligned the first ten 97% cross-correlated 
waveforms using their respective R-wave fiducial synchronization points, creating initial 
P, QRS and T wave signal-averaged templates for each channel.  The software then 
 5
added subsequent incoming beats to the signal averages only when the cross correlations 
between the incoming beats and the existing templates in each channel were > 97%14,15. 
If in any channel the cross correlation between the template beat and the new incoming 
beat was less than 97%, then the software rejected the beat for all channels. For HF QRS, 
the conventional R-wave onset and the S wave offset were applied to the HF QRS signals 
in software at the same time as bandpass filtering for isolation of only those QRS 
frequencies between 150 and 250 Hz14.  For the derived Frank-lead parameters, and for 
parameters of waveform complexity by SVD, the given wave within each channel was 
first referenced to the first 50 ms of the isoelectric T-P segment within that channel in 
order to eliminate any DC offset15.  
The following 12-lead HF QRS parameters were obtained at the end of signal 
averaged recordings: the total number of reduced amplitude zones (RAZ) present of the 
Abboud, Abboud-Percent and NASA types14,19; the overall “RAZ Score” for the given 
12-lead HF QRS ECG20; the sum of the HF QRS kurtosis values19 over the 12-leads; and 
the sum of the HF QRS root mean square (RMS) voltage values over the 12 leads (“RMS 
sum”)21.  HF QRS analyses were automatically performed in software for both the “CR” 
and the “V” precordial lead configurations14,19 and the highest (RAZ parameters) or 
lowest (kurtosis sum; RMS sum) overall value from the CR versus V precordial lead 
comparison was then automatically chosen for final HF QRS-related outputs. 
The following parameters were also obtained from the derived Frank leads at the 
end of signal averaging:  the spatial P wave duration and the mean spatial velocity of both 
the P wave22 and the QRS wave;  the spatial mean23,24 and spatial maximum25 QRS-T 
angles; the spatial ventricular gradient, including its individual components (i.e., spatial 
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mean QRS and T waves)23; the spatial ventricular activation time (VAT)26; and the so-
called “late potentials” parameters, including the filtered QRS duration (fQRSd), the 
RMS voltage of the terminal 40 ms of the filtered QRS complex (RMS40), and the 
duration of low amplitude (<40 uV) signal in the terminal filtered QRS complex 
(LAS40); i.e., after digital filtering between 40-250 Hz17. 
Finally, the following additional parameters of P, QRS and T waveform 
complexity were also obtained after signal averaging and SVD: 
1) The complexity ratio (CR) of  the given waveform (also known as principal 
component analysis ratio), which is the ratio of the second to the first eigenvalue27,28 of 
the given waveform, multiplied by 100, i.e.,  
CR = 
1
2100 ρρ×    
2) The relative “waveform residuum” (rWR) of the given waveform, which is the sum of 
the squares of the last 5 eigenvalues (or “non dipolar” components) of the given 
waveform divided by the sum of the squares of all eight eigenvalues18,29 of the given 
waveform, multiplied by 100, i.e.,  r  where ∑∑
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3)  The modified relative waveform residuum (mrWR) of the given waveform, which is 
the ratio of the sum of the squares of the third through the eighth eigenvalues of the given 
waveform to the sum of the squares of all eight eigenvalues of the given waveform, 
multiplied by 100, i.e.,   where ∑∑
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4) The “normalized 3-dimensional volume” (nV) of the given waveform, which is the 
product of the second and third eigenvalues of the given waveform divided by the square 
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of the first eigenvalue of the given waveform, multipled by 100,  i.e., nV =  ×100
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The mrWR and nV parameters are new parameters of waveform complexity introduced 
herein.  These new parameters particularly emphasize the contribution of the third 
eigenvalue in the numerator, thus making them distinct from better known CR and rWR 
parameters, which instead particularly emphasize the contribution of the second and 
fourth eigenvalues in the numerator, respectively. The rationale for the use of these new 
parameters relates to the fact that in nearly all healthy individuals studied thus far at 
NASA, the most relevant T-wave amplitudes are actually contained not in the first three 
eigenvectors (or in the “dipolar components”18,29), but rather only in the first two 
eigenvectors (unpublished data).  Thus, when disease occurs and the T-wave eigenvector 
energies start shifting into more downstream eigenvector components, these new indices 
are often more sensitive than the older indices, suggesting that in disease, T-wave 
energies may often be shifting not from eigenvector 3 into the even more downstream 
eigenvectors, but rather from eigenvector 2 (and/or from eigenvector 1 and 2) into 
eigenvector 3. 
C. Advanced ECG parameters derived from variability analyses. Time series 
(~256 beats)  for the RR and QT intervals were analyzed according to the 
recommendations of the Task Force of the European Society of Cardiology and the North 
American Society of Pacing and Clinical Electrophysiology8. For QT interval variability, 
besides using all of the standard leads, the first eigenvector and other “virtual leads” 
derived from SVD were also constructed and used in separate sets of analyses, inasmuch 
as these SVD-derived leads are less prone to noise and to other methodological artifacts 
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than is any standard lead QT signal, including lead II30.  Specific variability analyses 
included: 1) the standard deviation of normal-to-normal RR and QT intervals (SDNN RR 
and SDNN QT, respectively); 2) the root mean square of the successive interval 
difference of normal-to-normal RR and QT intervals (rMSSD RR and RMSSD QT, 
respectively); 3) the QT variability index (QTVI)31; and 4) several other time and 
frequency domain indices of the RR interval variability, including (see8): Triangular 
Indices (TI and TINN) from the 256-beat RR interval histogram; the percent of adjacent 
normal-to-normal RR intervals more than 50 ms apart (pNN50); and the very low (0.0-
0.04 Hz), low (0.04-0.15 Hz), high (0.15-0.40 Hz), and total (0.0-0.40 Hz) frequency 
powers of RR interval variability in natural log-transformed units (ln ms2/Hz) calculated 
using the Lomb periodogram32 method, and lastly, 4) “non-linear” HRV including alpha 
1 and alpha 2 (from detrended fluctuation analyses)33 and the first and second standard 
deviations (SD1 and SD2) as well as the cardiac interbeat autocorrelation coefficient of 
RR intervals (rRR) from the ~256-beat Poincaré plot34,35.  
Statistical Methods.  
Differences in parameters between groups were studied using nominal logistic 
regression and chi-square tests, with natural log transformation for all non-normally 
distributed data.  In addition, sensitivity and specificity information was generated for all 
studied parameters and further characterized through construction and analysis of 
receiver operating characteristic (ROC) curves.  All statistical analyses, including relative 
risk and survival analyses in relation to ECG findings in the FD group, were performed 
using SAS JMP software version 7.0 (Cary, NC). Differences between groups were 
considered significant at P < 0.05.  
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RESULTS    
After 4.5 years of follow-up, four of the 14 FD patients have experienced sudden 
death. Patient 11, a 51-year old female, died within a few weeks of data collection due to 
respiratory arrest in the context of pneumonia and hypoxic encephalopathy.  Patient 12, a 
16-year old male, died of a night-time cardiorespiratory arrest 6 months after data 
collection. He also had pneumonia at the time. Patient 13, a 25-year old female, had a 
syncopal episode in the bathroom two years after data collection which led to hypoxic 
encephalopathy, coma and subsequent death. Patient 4, a 20-year old male, suffered from 
chronic and progressive lung disease and was using a ventilator during physical 
rehabilitation slightly more than four years after data collection when he experienced 
pulseless cardiac arrest, presumptive asystole and sudden death.  
The advanced ECG parameters that most accurately predicted sudden death in the 
FD patients were the vagally-mediated HRV parameters, specifically the rMSSD, HF 
power, pNN50 and Poincaré SD1 of HRV. Patients 11, 12 and 13 all had especially low 
rMSSD HRV values at the time of data collection in 2003, whereas patient 4’s value fell 
closer to average for FDs at that time (Figure 1). A survival analysis with reference to the 
level of HRV rMSSD in FD patients at the time of the index data collection is shown in 
Figure 2.  The single best electrocardiographic predictor of sudden death in FD in this 
study was an rMSSD value less than 14 ms, which conferred a relative risk of 7.5.  
Summarized results for all advanced ECG parameters for the FD patients versus 
the age- and gender-matched healthy controls are shown in the Table. The ECG 
parameters that best separated the FD patients from the healthy controls were the P-wave 
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and QRS-wave mean spatial velocities, as well as the alpha 2 index of HRV.  However, 
there were significant differences between groups with respect to numerous parameters, 
including with respect to several different indices of HRV (especially the vagally-
mediated indices as noted), several voltage-related parameters, and several 
repolarization-related parameters (i.e., parameters of beat-to-beat QT variability, T-wave 
morphology, and the QTc and JTc intervals).  Seven of the 14 FD patients (50%, patients 
4, 6, 8-10, 12, 14) were electrocardiographically positive for LVH according to either the 
Cornell or Sokolow-Lyon voltage criteria12, two of these patients (4, 11) dying during the 
study. Echocardiograms were incidentally performed (for clinical purposes) in 11 of the 
14 FD patients, six of whom had evidence of LVH (patients 4, 5, 6, 7, 10, 14). A total of 
3 of the 14 FD patients (patients 4, 12, 14) had conventional ECG evidence for a prior MI 
on the basis of Anderson’s subset of Selvester’s criteria. Two of these patients (4, 12) 
later experienced sudden death. 
 
DISCUSSION 
The most important results from this study were that, first, diminished vagally-
mediated HRV is especially predictive of the propensity for sudden death in FD patients, 
and second, that FD patients have multiple conventional and advanced 
electocardiographic abnormalities (compared to age- and gender-matched healthy 
controls) that tend to suggest structural heart disease, occasionally prior MI, but 
especially LVH. 
Diminished vagally-mediated HRV and sudden death in FD. The finding that 
diminished vagally-mediated HRV is predictive of sudden death in FD might be 
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construed as paradoxical, at least prima facie, given that excessive or unopposed vagal 
activity (in relation to sympathetic activity) has often been implicated as a possible 
mechanism of death in FD, for example through induction of bradyarrhythmias or 
asystole, especially during sleep1,6,7. We believe that this apparent paradox can be 
resolved by perceiving the reduced vagally-mediated HRV not as a direct cause of 
sudden deaths, but rather as an effect of a concurrent pathological process that itself 
increases the risk of sudden death in FD while at the same time diminishing vagally-
mediated HRV. That concurrent pathological process is hypoxia, and its presence is at 
least indirectly reflected in the fact that three of the four FD patients who had sudden 
death in this study were suffering from either acute or chronic pulmonary disorders at the 
time of their deaths. Hypoxia occurring as a result of sleep apnea is well known to reduce 
even daytime HRV, especially those parameters of HRV that are vagally mediated, 
regardless of whether the apnea is of the obstructive or central type36-38.  
This therefore shifts our attention to the role of concomitant hypoxia and 
pulmonary involvement in the outcomes of patients with FD.  Death from pulmonary 
complications is the leading cause of death in FD,2,3 although sudden death is a frequent 
cause of death, with most sudden deaths occurring at night3. In one study examining sleep 
recordings in FD, all FD patients demonstrated breathing disorders (especially central 
apnea) during sleep and 77% had more than 50 apneic spells per night39. In addition, FD 
patients are known to be especially susceptible to bradycardia and hypotension during 
chemoreflex stimulation associated with periods of apnea and hypoxia40.  This is 
presumably due (at least in part) to deficient baroreflex-mediated attenuation of apnea-
induced bradycardia41 in FD patients, baroreflex deficiency being well characterized in 
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FD42. In healthy individuals, hypoxia and chemoreflex activation during apnea or 
hypoventilation generally leads to coactivation of vagal and sympathetic pathways41,43. 
Simultaneous vagal and sympathetic activation during apnea may help prevent heart rate 
from becoming excessively high, thus ensuring sufficient diastolic filling and cardiac 
output43 without undue increases in myocardial oxygen demand.  In FD patients, efferent 
vagal and sympathetic pathways are often both deficient, as is the baroreflex 
response40,42.  This combination of abnormalities, along with the lack of an appropriate 
tachypnea response to hypoxia and inappropriate posthyperventilatory apnea in FD, 
appears responsible in some way for the central respiratory depression that occurs in 
response to even moderate levels of hypoxia40.  Particularly in the context of some other 
condition in FD that commonly exacerbates hypoxia, such as aspiration pneumonia, 
restrictive pulmonary problems due to scoliosis, anemia, sleep apnea, etc4, this central 
respiratory depression may abet yet more hypoxia and eventually result in life-
threatening hypotension or bradyarrhythmia or at worst respiratory or cardiac arrest40.  
The question remains, however, ‘through what mechanism precisely’? 
Although it has not been previously addressed in the FD literature (to our 
knowledge), the release of adenosine by hypoxic tissues makes a major contribution to 
the decreases in respiration and heart rate that occur during systemic hypoxemia44-48. 
Adenosine has pronounced depressant effects on cardiac pacemakers49, and at least in 
animals, the occurrence of bradyarrhythmia during hypoxia may be independent of vagal 
tone and driven by endogenous adenosine release47,48. Adenosine accumulation has also 
been implicated in the pathogenesis of vasovagal syncope50, a condition commonly 
experienced in FD42, and in bronchoconstriction51.  Perhaps most importantly, adenosine 
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accumulation in the brain is also known to be associated with prolonged respiratory 
depression44,45.  It is therefore tempting to speculate that therapeutic strategies that focus 
on attenuating adenosine-induced bradyarrhythmia and respiratory inhibition may be 
beneficial in helping to prevent sudden death in FD.  
Methylxanthines such as aminophylline and theophylline are competitive 
antagonists to adenosine.  Theophylline rapidly resolves the central respiratory 
depression associated with adenosine and in cats can completely prevent an otherwise 
long-lasting adenosine-associated respiratory depression when given prior to exposure to 
hypoxia44,45. Methylxanthines have also been shown to significantly increase HRV, 
particularly in the HF (“vagally-mediated”) band and to normalize autonomic function in 
premature neonates52.  This autonomic normalization might also be exemplified by 
theophyilline’s role in the treatment of neurocardiogenic syncope53,54.  Moreover, 
theophylline therapy has been shown to significantly reduce apneic episodes and improve 
arterial oxygen saturation in patients with central sleep apnea55. Finally, aminophylline 
therapy is often successful in reversing not only atropine-resistant AV block during 
inferior myocardial infarction56, but also, importantly, bradyasystolic cardiac arrest that is 
resistant to both atropine and epinephrine57,58. While theophylline can increase gastro-
esophageal reflux59, a common problem in FD60,61, the fact that a substantial portion of 
FD patients are now undergoing fundoplication and gastrostomy procedures60,61 might 
make theophylline a tolerable therapeutic option in many patients.  Pending controlled 
trials designed to test theophylline’s efficacy in FD, the drug might certainly complement 
other measures that are presently used to prevent or ameliorate the effects of hypoxemia, 
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such as oxygen therapy itself and CPAP4, especially in FD patients who may be at 
increased risk for sudden death as indicated by low levels of vagally-mediated HRV. 
Although pacemaker implantation in FD patients may reduce the incidence of 
fatal bradyarrhythmia and syncope5,62, it nevertheless does not entirely eliminate these 
conditions, and some FD patients with implanted pacemakers have still experienced 
cardiac arrest5. Thus, pacemaker placement alone may not be sufficient to prevent sudden 
death in all cases. Gold-von Simson et al.5 have attributed the lack of complete success 
with pacemakers to the possible overriding effects of hypoxia and central respiratory 
depression. Assuming that ventricular arrhythmias are not the cause of death in these 
recalcitrant cases5 (if so, then pacemaker-defibrillators would be indicated), it is possible 
that the inability to prevent fatal bradyarrhythmia in some pacemaker-resistant cases 
relates to the overriding depressant effects of adenosine accumulation – an hypothesis 
that remains to be investigated.  
Changes in other ECG parameters. Although they were not as predictive of 
sudden death in FD as the vagally-mediated HRV parameters, the ECG parameters that 
best separated the FD patients from the healthy controls were the P- and QRS-wave mean 
spatial velocities, as well as the alpha 2 index of HRV.  The P- and QRS-wave spatial 
velocities are measures of the rate of change of the size of the respective signal22 and 
likely relate to conduction velocity.  Therefore, the enhancement of these spatial 
velocities would be consistent with a relative diminution in efferent vagal activity in FD, 
given that cardiac vagal activity is known to diminish conduction velocity (i.e., has 
negative dromotropic effects)63. The relative diminution of efferent cardiac vagal activity 
in FD is also of course reflected in the decreased vagally-mediated HRV parameters 
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themselves (including decreased SD1/SD2 ratios on the Poincaré plot), and also with the 
increased resting heart rates, LF/HF ratios, values of alpha 1 and 2 (alpha 1 values 
typically paralleling those in the LF/HF ratio64), and the Poincaré plot interbeat 
autocorrelation coefficients (rRR)35 in FD patients.  
As noted, half of the FD patients were electrocardiographically positive for LVH 
by either Cornell or Sokolow-Lyon voltage criteria. These findings are also consistent 
with the overall larger electrocardiographic voltages found in the FD patients, as well as 
with the increased spatial QRS-T angles (which may reflect ventricular enlargement23,26) 
found in the FD group compared to the healthy controls.  These are important findings 
given that LVH (and increased spatial QRS-T angle24) is by itself a significant risk factor 
for cardiovascular and total mortality65,66, and that the propensity for sudden death also 
increases with the degree of LVH in other genetic conditions that commonly result in 
sudden death in young individuals67.  In the context of hypoxia in FD, LVH might 
certainly predispose affected individuals to further increased risk, given that LVH 
increases myocardial oxygen demand and also arrythmogenesis68. In terms of the four FD 
patients who died during this study, three of them had either electrocardiographic LVH at 
the time of data collection (patient 12), echocardiographic LVH at some point in time 
(patient 12), or both (patient 4).  The only patient who died during this study who did not 
have any evidence for LVH was patient 11.  However, an echocardiogram was also never 
clinically obtained from patient 11.  Although five of ten of the FD patients who did not 
die during this study also had evidence for LVH (four of nine echocardiographically), 
these results nonetheless suggest that LVH may be yet another factor contributing to the 
risk for sudden death in FD.  Examination of a larger historical FD patient database of 
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echocardiographic results from NYU (unpublished) demonstrates that roughly one in five 
FD patients who have had echocardiograms have developed at least mild degrees of 
echocardiographic LVH. Several patients in this larger database who did not have LVH 
on an initial echocardiogram later developed it, suggesting that LVH in FD might be 
most obviously associated with progressive, unrelenting hypertension – a condition that 
often goes untreated in FD due to coexisting blood pressure lability1.  The presence of 
sleep apnea in FD might also exacerbate daytime hypertension and LVH69, with untreated 
hypertension also likely contributing to decreased HRV70.  
It has previously been noted that abnormal repolarization, as inferred from 
prolonged QTc or JTc electrocardiographic intervals, may also be associated with an 
increased risk for syncope and sudden death in FD5,7.  Although QTc and JTc intervals 
were also prolonged in FD patients (versus healthy controls) in this study, there was no 
clear relationship between the degree of QTc/JTc prolongation and the risk for sudden 
death.  Several more advanced parameters of repolarization instability were also 
significantly increased in FD patients relative to healthy controls, including the beat-to-
beat indices of QT variability and essentially all parameters of T-wave complexity 
derived from singular value decomposition (Table).  However, none of these more 
advanced measures of repolarization instability was very predictive of sudden death, and 
in fact many of the surviving FD patients had more severe increases in these parameters 
than did those with sudden death.  It should be recalled that structural heart disease (i.e., 
prior MI, LVH)  and even hypertension alone71 are associated with increased QTc 
intervals. Hypertension alone can also increase the QT variability index72, whereas 
elevations in heart rate alone can increase the T-wave residuum73.  Thus, the changes in 
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both conventional and advanced ECG parameters of repolarization in FD may be more 
reflective of underlying hypertension, LVH or other structural heart disease than of the 
propensity for sudden death per se. Finally, it should also be noted that the filtered QRS 
duration in this study was not different between FD patients and healthy controls, in 
contrast to a prior study74, nor were parameters of HF QRS, and that these parameters 
were also not useful in predicting the propensity for sudden death in the FD group. 
In conclusion, we found that low vagally-mediated HRV is especially predictive 
of the propensity for sudden death in FD patients, and that FD patients have multiple 
conventional and advanced electocardiographic abnormalities (compared to age- and 
gender-matched healthy controls) that tend to suggest structural heart disease, especially 
LVH. We interpret the reduced vagally-mediated HRV not so much as a direct cause of 
sudden deaths but rather as an effect of concurrent pathological processes, especially 
hypoxia, that themselves increase the risk of sudden death in FD while at the same time 
diminishing vagally-mediated HRV.  Possible reasons for hypoxia in FD are well known 
and include (especially) pulmonary disease and sleep apnea.  These same disease 
processes, along with hypertension, can also contribute to ventricular hypertrophy and to 
ischemic heart disease, which in turn may further exacerbate the propensity for sudden 
death in FD.  We suggest that adenosine may play an important role in mediating 
episodes of vasovagal syncope, bradyarrhythmias, central respiratory depression and 
sudden death in FD, possibly independently of vagal tone, and that therefore adenosine 
antagonist medications such as theophylline might be useful in helping to prevent such 
episodes.  A clinical trial that would prospectively evaluate the efficacy of 
methyxanthines such as theophylline in FD patients might therefore be warranted, 
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especially now that fundoplication and gastrostomy are so common in FD, potentially 
improving tolerance to methylxanthine-type medications.  Finally, we suggest that 
vagally-mediated parameters of HRV should be followed regularly in FD (with 
avoidance of HRV measurements during tachycardia or dysautonomic crises), along with 
both electocardiographic and echocardiographic studies focused on the detection, 
prevention and optimal management of hypertensive heart disease. 
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TABLE 
 
ECG PARAMETERS 
FAMILIAL 
DYSAUTONOMIA CONTROLS 
P 
VALUE 
AREA 
UNDER 
ROC 
CURVE (If 
P < 0.05) 
     
Conventional ECG     
Heart Rate (beats/min) 85 ± 23 68 ± 10 0.007 0.77 
PR interval (ms) 125 ± 44 148 ± 23 NS  
QRS interval (ms) 94 ± 12 93 ± 8 NS  
QTc interval (ms, Bazett-corrected) 444 ± 64 403 ± 18 0.019 0.74 
JTc interval (ms, Bazett-corrected) 350 ± 57 310 ± 19 0.005 0.79 
P axis (°, frontal plane) 52 ± 23 51 ± 13 NS  
QRS axis (°, frontal plane) 78 ± 15 80 ± 26 NS  
T axis (°, frontal plane) 40 ± 70 39 ± 21 NS  
12 Lead Area (uV*s) 466 ± 129 401 ± 79 NS  
12 Lead Voltage (mV) 24 ± 7 18 ± 3 0.007 0.78 
Sokolow-Lyon voltage (mV)    3.3 ± 0.9 2.5 ± 0.7 0.016 0.80 
Cornell Voltage (mV) 2.4 ± 1.1 1.4 ± 0.6 <0.001 0.84 
Cornell Product (mV*ms) 216 ± 83 133 ± 57 0.003 0.80 
P wave duration (ms)  89 ± 31 97 ± 10 NS  
     
Heart Rate Variability (RR interval Variability)    
SDNN (ms)        34.4 ± 18.2 55.69 ± 29.62 0.021 0.71 
rMSSD (ms)       21.0 ± 11.2 51.0 ± 35.0 <0.001 0.83 
pNN50 (%)          4.7 ± 6.5 26.3 ± 25.0 0.001 0.83 
Triangular Index (ms)    8.2 ± 3.5 12.7 ± 5.1 0.007 0.76 
TINN (ms)        122.8 ± 49.4 205.4 ± 87.2 0.003 0.80 
SD1 of Poincaré plot (ms)             15.2 ± 8.3 36.2 ± 24.8 <0.001 0.82 
SD2 of Poincaré plot (ms)          45.7 ± 25.0 69.5 ± 34.8 0.038 0.70 
rRR of Poincaré plot (ms)          0.77 ± 0.19 0.60 ± 0.15 0.009 0.82 
SD1/SD2 ratio 0.34 ± 0.17 0.50 ± 0.12 0.006 0.82 
Ln VLF Power (Ln ms²/Hz) 5.3 ± 1.5 6.1 ± 0.9 NS  
Ln LF Power (Ln ms²/Hz) 4.9 ± 1.6 6.0 ± 1.3 0.039 0.71 
Ln HF Power (Ln ms²/Hz) 4.3 ± 1.6 6.3 ± 1.4 <0.001 0.86 
Ln Total Power (Ln ms²/Hz) 6.3 ± 1.4 7.4 ± 1.1 0.011 0.75 
LF/HF ratio 2.3 ± 1.5 1.0 ± 1.1 0.013 0.79 
Alpha1 (units)          1.11 ± 0.26 0.91 ± 0.22 0.035 0.71 
Alpha2 (units)         1.13 ± 0.22 0.84 ± 0.17 <0.001 0.87 
     
QT Interval Variablity      
SDNN QTV (ms, 1st Eigenvector)  3.6 ± 2.8 2.6 ± 1.5 NS  
rMSSD QTV (ms, 1st Eigenvector) 3.2 ± 4.1 1.8 ± 0.8 NS  
QTV index (units, 1st Eigenvector) -1.56 ± 0.50 -1.94 ± 0.28 0.012 0.75 
SDNN_QT (ms, lead II) 4.1 ± 3.5 2.7 ± 1.5 NS  
rMSSD_QT (ms, lead II) 3.5 ± 4.2 2.0 ± 1.1 NS  
QTV index (units, lead II) -1.44 ± 0.49 -1.87 ± 0.26 0.002 0.83 
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High Frequency QRS ECG (150-250 Hz)    
RAZ score (units) 25 ± 13 36 ± 25 NS  
12-lead RMS voltage sum (uV) 60 ± 20 47 ± 21 NS  
12-lead kurtosis sum (units) 46 ± 5 45 ± 9 NS  
Reduced Amplitude Zone A (number) 5 ± 3 7 ± 3 NS  
Reduced Amplitude Zone AP (number) 3 ± 2 5 ± 3 NS  
Reduced Amplitude Zone N (number) 1 ± 1 2 ± 3 NS  
     
"3D ECG" parameters (using derived Frank X, Y, Z lead SAECG)  
     
P-wave Mean Spatial Velocity (mV/s)      5.6 ± 3.2 3.5 ± 0.5 <0.001 0.92 
QRS-wave Mean Spatial Velocity (mV/s) 76.5 ± 31.2 53.7 ± 9.9 <0.001 0.86 
Spatial P-wave Duration (ms)     119 ± 7 116 ± 17 NS  
Spatial Mean QRS (mV*s) 0.04 ± 0.02 0.04 ± 0.01 NS  
Mean Spatial QRS-T Angle (°) 76 ± 48 44 ± 19 0.017 0.71 
Spatial Ventricular Activation Time (ms)    41 ± 5 43 ± 6 NS  
Spatial Ventricular Gradient (mV*s)     0.072 ± 0.034 0.091 ± 0.016 NS  
Maximum Spatial QRS-T Angle (°) 54 ± 41 29 ± 15 0.02 0.71 
     
"Late Potentials" parameters (using derived Frank X, Y, Z lead SAECG, 40-250 Hz) 
Filtered QRS duration (ms) 88.0 ± 9.0 87.9 ± 9.6 NS  
RMS 40 (uV)          212.5 ± 129.0 149.7 ± 52.5 NS  
LAS (ms)            10.9 ± 9.2 13.4 ± 7.2 NS  
     
Waveform Complexity (by singular value decomposition and signal averaging) 
Modified complexity ratio of T wave(%) 0.56 ± 0.88 0.04 ± 0.04 0.002 0.76 
PCA ratio of T wave (%) 26.6 ± 15.2 15.5 ± 4.9 0.003 0.79 
Relative T-wave Residuum (%) 0.099 ± 0.157 0.008 ± 0.005 0.002 0.74 
Normalized T-wave Volume (%) 2.0 ± 3.5 0.3 ± 0.2 <0.001 0.79 
PCA ratio of QRS wave (%) 47.4 ± 14.4 44.8 ± 21.8 NS  
Modified complexity ratio of QRS (%) 2.1 ± 2.5 1.0 ± 0.5 0.044 0.68 
Relative QRS-wave Residuum (%) 0.52 ± 0.48 0.23 ± 0.16 0.016 0.78 
Normalized QRS-wave Volume (%) 5.9 ± 3.5 4.6 ± 4.0 NS  
PCA ratio of P wave (%) 30.7 ± 16.5 32.8 ± 15.4 NS  
Modified complexity ratio of P wave (%) 1.9 ± 1.3 1.1 ± 0.5 0.028 0.69 
Relative P-wave Residuum (%) 0.41 ± 0.20 0.31 ± 0.15 NS  
Normalized P-wave Volume (%) 4.1 ± 3.4 3.1 ± 2.0 NS  
 
Values shown are means ± standard deviations. N = 14 patients with Familial 
Dysautonomia and 14 age- and gender matched healthy controls.  ROC, receiver 
operating characteristic. NS, not significant.  See text for parameter abbreviations.  
 
 26
FIG. 1 
rMSSD values in 14 FD patients 
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FIG. 2 
 
rMSSD Survival Plot 
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Figure Legends:  
 
Figure 1.  Heart rate variability rMSSD values for the 14 FD patients. Living patients are 
represented by black bars, and the four patients who experienced sudden death by 
patterned bars.  Although patient 4 had a normal rMSSD value at the time of index data 
collection (slightly less than 4.5 years prior to death), his vagally-mediated HRV 
parameters fell precipitously at subsequent clinical data collection points as his 
pulmonary disease progressed (data not shown). Sinus tachycardia was present in patients 
13 and 14 and likely contributed to their low rMSSD values. 
 
Figure 2.  The solid line represents FD patients with rMSSD values > 14 ms and the 
dotted line FD patients with rMSSD values < 14 ms.  Time represents time in years from 
the index data collection, and Surviving the proportion of individuals in the given rMSSD 
group still alive at the given Time.  
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